UNITEDTable STATES SECURITIESof AND EXCHANGE COMMISSION Contents

Item 3.01.Table Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Contents

Item 9.01Table Financialof Statements and Exhibits. Contents

PursuantTable to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Contents

~~Washington,~~UNITED ~~D.C.~~STATES SECURITIES ~~20549~~AND EXCHANGE COMMISSION

~~FORM~~Washington, ~~8-K~~D.C. 20549

~~CURRENT~~FORM ~~REPORT~~8-K ~~Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934~~

~~Date~~CURRENT ofREPORT Pursuant ~~Report~~to Section 13 OR 15(~~Date~~d) of The ~~earliest~~Securities ~~event~~Exchange ~~reported):~~Act ~~April 8,~~of ~~2009~~1934

~~IDM~~Date ~~PHARMA~~of Report (Date of earliest event reported): May 11, ~~INC.~~ 2009

~~(Exact~~IDM ~~name~~PHARMA, ~~of registrant as specified in its charter)~~INC.

Delaware	0-19591	33-0245076
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

(Exact name of registrant as specified in its charter)

9 Parker, Suite 100
Irvine, California		92618
(Address of principal executive offices)		(Zip Code)


Delaware (State or other jurisdiction of incorporation)		0-19591 (Commission File Number)		33-0245076 (IRS Employer Identification No.)

~~Registrant’s~~9 ~~telephone~~Parker, ~~number~~Suite 100 Irvine, ~~including~~California ~~area~~(Address ~~code~~of principal executive offices) 92618 (~~949~~Zip Code) ~~470-4751~~

~~(Former~~Registrant’s ~~name~~telephone ~~or former address~~number, ifincluding ~~changed~~area ~~since~~code ~~last report.~~(949) 470-4751

~~Check~~(Former ~~the~~name ~~appropriate~~or ~~box~~former ~~below~~address, if ~~the~~changed ~~Form~~since ~~8-K~~last ~~filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A~~report.~~2. below~~):

oCheck ~~Written~~the ~~communications~~appropriate ~~pursuant~~box below if the Form 8-K filing is intended to ~~Rule 425~~simultaneously satisfy the filing obligation of the registrant under any of the ~~Securities~~following ~~Act~~provisions (17see ~~CFR~~General ~~230~~Instruction A.~~425~~2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

oTABLE ~~Pre-commencement~~OF ~~communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))~~ CONTENTS

oItem ~~Pre-commencement~~2.02. ~~communications~~Results ~~pursuant~~of toOperations ~~Rule 13e-4(c)~~and ~~under~~Financial ~~the~~Condition ~~Exchange~~Item ~~Act~~9.01. ~~(17~~Financial ~~CFR 240.13e~~Statements and Exhibits SIGNATURES INDEX TO EXHIBITS EX-~~4(c))~~ 99.1

~~On April~~Item ~~8, 2009, IDM Pharma, Inc~~2. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the continued listing requirements of The Nasdsq Global Market under Nasdaq Marketplace Rule 4450(a)(3), which requires that companies listed on The Nasdaq Global Market must maintain a minimum of $10,000,000 in stockholders’ equity02. In ~~addition,~~Results ~~the Company does not meet the continued listing requirements under The Nasdaq Global Market’s alternate maintenance standard. This notification has no immediate effect on the listing~~ of ~~the~~Operations ~~Company’s~~and ~~common~~Financial ~~stock on The Nasdaq Global Market~~Condition.

~~The~~On ~~Company has until April~~May 2311, 2009, towe ~~provide~~issued ~~Nasdaq~~ a ~~specific~~press ~~plan~~release toannouncing, ~~achieve~~among ~~and~~other ~~sustain compliance~~things, ~~with~~our ~~all~~financial ~~Nasdaq Global Market listing requirements. If the Company submits the plan and~~results itfor ~~is accepted by Nasdaq,~~ the ~~Company~~quarter ~~may~~ended ~~be granted a period of up to 105~~March ~~days from April 8~~31, 2009 ~~within which the Company can regain compliance with such listing requirements~~. IfA ~~Nasdaq determines~~copy ~~that~~of ~~the~~this ~~Company’s~~press ~~plan~~release is ~~not~~attached ~~sufficient~~as ~~to achieve and sustain compliance, it will provide written notice that the Company’s securities will be delisted~~Exhibit 99.1 ~~At such time, the Company~~to ~~may~~this ~~appeal~~Current ~~the decision to a Nasdaq Listing Qualifications Panel~~Report.

~~Alternatively~~The information in this Item 2.02 and Item 9.01, ~~the~~and ~~Company~~Exhibit 99.1 ~~may~~attached ~~apply~~hereto, tois ~~transfer~~being furnished ~~its~~and ~~securities~~shall tonot ~~The~~be ~~Nasdaq~~deemed ~~Capital~~“filed” ~~Market.~~for Inthe purposes of Section 18 of the Securities Exchange ~~order~~Act toof ~~transfer~~1934, ~~the~~as ~~Company~~amended, ~~must~~or ~~satisfy~~otherwise ~~the~~subject ~~continued~~to ~~inclusion~~the ~~requirements~~liabilities ~~for~~of that ~~market.~~section, nor shall it be Ifdeemed ~~the~~incorporated ~~Company~~by ~~submits~~reference ain ~~transfer~~any ~~application,~~filing under the ~~initiation~~Securities Act of ~~delisting~~1933, ~~proceedings~~as ~~will~~amended, beor ~~stayed~~under ~~pending~~the ~~Nasdaq’s~~Securities ~~review~~Exchange Act of ~~the~~1934, ~~transfer~~as ~~application~~amended, regardless of any general incorporation language in such filing.

~~The Company is currently evaluating whether to file the compliance plan with Nasdaq or to apply to transfer to the Nasdaq Capital Market~~Item 9.01. ~~Should~~Financial ~~the~~Statements ~~Company choose to present a plan to achieve~~ and ~~sustain~~ ~~compliance with all Nasdaq Global Market listing requirements, there can be no assurance that such plan will be sufficient to avoid delisting~~Exhibits. ~~Should the Company choose to apply to~~ ~~transfer its securities to The Nasdaq Capital Market, there can be no assurance that such application will be approved.~~

The Company issued a press release regarding this notice on April 13, 2009, which is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.


(c)		Exhibits

99.1		Press release of IDM Pharma, Inc. dated May 11, 2009.

~~(d) Exhibits~~SIGNATURES

Exhibit No.		Description
99.1		IDM Pharma, Inc. press release.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGNATURES


	IDM PHARMA, INC.
Date: May 11, 2009	By:	/s/ Robert J. De Vaere
		Robert J. De Vaere
		Senior Vice President, Finance and Administration and Chief Financial Officer

IDM PHARMA, INC.

Date: April 13, 2009

/s/ Robert J. De Vaere Robert J. De Vaere

Senior Vice President, Finance and Administration

and Chief Financial Officer

INDEX TO EXHIBITS

INDEX TO EXHIBITS


Exhibit No.		Description

99.1		Press release of IDM Pharma, Inc. dated May 11, 2009.

Exhibit No.		Description
99.1		IDM Pharma, Inc. press release.

Filing Compare · IDM PHARMA, INC.